Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday

Arbutus Biopharma (NASDAQ:ABUS) is expected to be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect Arbutus Biopharma to post earnings of ($0.08) per share and revenue of $2.20 million for the quarter.

Arbutus Biopharma Price Performance

Shares of ABUS stock opened at $3.44 on Thursday. The stock’s fifty day moving average price is $3.31 and its 200 day moving average price is $3.66. Arbutus Biopharma has a 1-year low of $2.30 and a 1-year high of $4.72. The company has a market cap of $650.90 million, a price-to-earnings ratio of -7.99 and a beta of 1.78.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. JMP Securities lifted their target price on Arbutus Biopharma to $5.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. Chardan Capital reiterated a “buy” rating and issued a $5.00 price objective (up previously from $4.50) on shares of Arbutus Biopharma in a research note on Wednesday, November 20th. Finally, StockNews.com cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Arbutus Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.